Literature DB >> 30010848

Development of significant tricuspid regurgitation over time and prognostic implications: new insights into natural history.

Edgard A Prihadi1,2, Pieter van der Bijl1, Erhan Gursoy1, Rachid Abou1, E Mara Vollema1, Rebecca T Hahn3, Gregg W Stone3, Martin B Leon3, Nina Ajmone Marsan1, Victoria Delgado1, Jeroen J Bax1.   

Abstract

Aims: To evaluate the risk factors influencing the development of significant (moderate and severe) tricuspid regurgitation (TR), and its impact on all-cause mortality in large registry of referral centre. Methods and results: In 1000 patients (mean age 68 ± 13 years; 50.9% male) with documented significant TR, clinical, and echocardiographic data were retrospectively analysed when the echocardiogram showed none/mild TR. Patients with congenital heart disease were excluded. The study population was divided into quartiles according to the time interval between the two echocardiograms: Group 1: ≤1.2 years, n = 251; Group 2: 1.3-4.7 years, n = 248, Group 3: 4.8-8.9 years, n = 251; Group 4: ≥9.0 years, n = 250. Baseline age [odds ratio (OR) 1.02], presence of pacemaker and defibrillator lead (OR 1.59), presence of mild (vs. none) TR (OR 8.96), reduced tricuspid annulus plane systolic excursion (OR 0.86), and tricuspid annulus dilation (OR 1.06) were independently associated with development of significant TR in a short period of time. Any valvular surgery (without concomitant tricuspid surgery) occurring between both echocardiograms was also associated with a higher risk of fast development of significant TR (OR 1.58). During a median follow-up of 2.9 years after the second echocardiogram (with significant TR), 42.1% patients died. Patients with fast development of significant TR showed worse survival than patients with slower significant TR development (log rank P = 0.001). Fast development of significant TR was independently associated with all-cause mortality (hazard ratio per preceding year of development: 0.92, confidence interval 0.90-0.94; P < 0.001).
Conclusion: By identifying patients at increased risk of developing significant TR, close echocardiographic surveillance can be indicated permitting effective therapy at an earlier stage to improve survival.

Entities:  

Mesh:

Year:  2018        PMID: 30010848     DOI: 10.1093/eurheartj/ehy352

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  13 in total

1.  Added value of transthoracic 2D echocardiographic en face view of the tricuspid valve.

Authors:  Matthias Schneider; Thomas Binder
Journal:  Wien Klin Wochenschr       Date:  2020-01-13       Impact factor: 1.704

Review 2.  Sex Differences and Similarities in Valvular Heart Disease.

Authors:  Jacqueline T DesJardin; Joanna Chikwe; Rebecca T Hahn; Judy W Hung; Francesca N Delling
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

Review 3.  Three-Dimensional Echocardiography for Tricuspid Valve Assessment.

Authors:  Claudia Escabia; Antoni Bayes-Genis; Victoria Delgado
Journal:  Curr Cardiol Rep       Date:  2022-09-01       Impact factor: 3.955

Review 4.  Valvular Heart Disease Epidemiology.

Authors:  John Sukumar Aluru; Adam Barsouk; Kalyan Saginala; Prashanth Rawla; Alexander Barsouk
Journal:  Med Sci (Basel)       Date:  2022-06-15

Review 5.  Transcatheter therapies for severe tricuspid regurgitation. Quo vadis?

Authors:  Brunilda Alushi; Kourosh Vathie; Holger Thiele; Alexander Lauten
Journal:  Herz       Date:  2020-05-28       Impact factor: 1.443

Review 6.  Tricuspid valve disease: diagnosis, prognosis and management of a rapidly evolving field.

Authors:  Lluis Asmarats; Maurizio Taramasso; Josep Rodés-Cabau
Journal:  Nat Rev Cardiol       Date:  2019-09       Impact factor: 32.419

7.  Progression of Tricuspid Regurgitation After Surgery for Ischemic Mitral Regurgitation.

Authors:  Philippe B Bertrand; Jessica R Overbey; Xin Zeng; Robert A Levine; Gorav Ailawadi; Michael A Acker; Peter K Smith; Vinod H Thourani; Emilia Bagiella; Marissa A Miller; Lopa Gupta; Michael J Mack; A Marc Gillinov; Gennaro Giustino; Alan J Moskowitz; Annetine C Gelijns; Michael E Bowdish; Patrick T O'Gara; James S Gammie; Judy Hung
Journal:  J Am Coll Cardiol       Date:  2021-02-16       Impact factor: 24.094

8.  Clinical performance and exercise hemodynamics in patients with severe secondary tricuspid regurgitation and chronic atrial fibrillation.

Authors:  Jesper K Jensen; Tor S Clemmensen; Christian A Frederiksen; Joachim Schofer; Mads J Andersen; Steen H Poulsen
Journal:  BMC Cardiovasc Disord       Date:  2021-06-04       Impact factor: 2.298

9.  Natural course of tricuspid regurgitation and prognostic implications.

Authors:  Marwin Bannehr; Christoph Roland Edlinger; Ulrike Kahn; Josephin Liebchen; Maki Okamoto; Valentin Hähnel; Victoria Dworok; Fabian Schipmann; Tanja Kücken; Karin Bramlage; Peter Bramlage; Anja Haase-Fielitz; Christian Butter
Journal:  Open Heart       Date:  2021-02

Review 10.  Global epidemiology of valvular heart disease.

Authors:  Sean Coffey; Ross Roberts-Thomson; Alex Brown; Jonathan Carapetis; Mao Chen; Maurice Enriquez-Sarano; Liesl Zühlke; Bernard D Prendergast
Journal:  Nat Rev Cardiol       Date:  2021-06-25       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.